• 20 April 2018

    Summit Therapeutics ends dosing in PhaseOut DMD trial

    Summit Therapeutics has completed patient dosing in the PhaseOut DMD clinical trial, a Phase II study of ezutromid to treat patients with duchenne muscular dystrophy (DMD), the most common and...

  • 19 April 2018

    Asahi starts enrolment in Phase III trial of isavuconazole

    Asahi Kasei Pharma has started enrolling patients in a Phase III trial of isavuconazole to treat deep-seated mycosis, comprised of invasive aspergillosis, chronic pulmonary aspergillosis, mucormycosis and cryptococcosis.